Insulin Price-Fixing Antitrust & Consumer Fraud Class Action
Case Overview
Insulin, first developed in the 1920s, remains a daily life-sustaining necessity for approximately 8 million Americans with diabetes. Despite being a mature product with no new active ingredient patents, the list prices for insulin analog products manufactured by Eli Lilly, Novo Nordisk, and Sanofi tripled between 2002 and 2013 and continued to rise thereafter, with some formulations exceeding $300 per vial. Plaintiffs in this New Jersey class action allege that the three insulin manufacturers secretly coordinated their pricing strategies and paid large rebates to pharmacy benefit managers (PBMs) in exchange for preferred formulary placement — a scheme that inflated list prices while insulating manufacturers and PBMs from competition, leaving uninsured and underinsured patients to bear the full artificial cost.
The litigation has drawn intense Congressional scrutiny and public attention, with Senate investigations confirming the alleged price-coordination dynamics. In March 2023, Eli Lilly unilaterally announced it would cap insulin prices at $35 per month, and Novo Nordisk and Sanofi followed. These moves, while welcomed, were made in the shadow of the litigation and federal legislative pressure under the Inflation Reduction Act's Medicare insulin cap. Sanofi reached a preliminary class settlement in 2023; cases against Lilly, Novo Nordisk, and the PBMs remain active. Plaintiffs seek damages for the excess costs paid by class members, injunctive relief, and disgorgement of ill-gotten profits under federal antitrust law and state consumer protection statutes.
Who May Qualify
U.S. residents who purchased insulin (including Humalog, Lantus, NovoLog, Basaglar, Toujeo, or other analog insulins) at retail pharmacies and paid out-of-pocket or co-pay amounts based on the artificially inflated list price, generally between 2009 and the present. This may include uninsured patients, those with high-deductible health plans, and patients in the Medicare Part D coverage gap ('donut hole').
Frequently Asked Questions
Who can join the insulin price-fixing class action lawsuit?
Diabetic patients who purchased insulin out-of-pocket or paid inflated co-pays based on list prices — particularly those who were uninsured, underinsured, or fell into the Medicare Part D donut hole — may qualify. The class period generally covers purchases from around 2009 onward. Consult a class action attorney to assess your eligibility.
Did the insulin companies already settle the lawsuit?
Sanofi reached a preliminary class settlement in 2023, and Eli Lilly and Novo Nordisk announced voluntary $35/month price caps. However, the core antitrust litigation against all three manufacturers and major pharmacy benefit managers is still ongoing, and final settlement terms are not yet established for all defendants.
Why did insulin prices get so high if the drug is 100 years old?
Plaintiffs allege that insulin manufacturers and pharmacy benefit managers engaged in a coordinated scheme of inflating 'list prices' while offering large confidential rebates to PBMs, creating an artificial pricing system that benefited both parties but harmed patients. Despite insulin's old formula, manufacturers introduced incremental reformulations to maintain market exclusivity and justify price increases.
Related Cases
National Association of Realtors (NAR) Commission Antitrust Settlement
Kroger / Albertsons Proposed Merger Antitrust Class Action